In-Vitro Colorectal Cancer Screening Tests Market by Product - Global Industry Analysis and Forecast to 2022

2018-05-30 / 3800.00 / Pharma & Healthcare / 95 Pages

Description

Industry Outlook and Trend Analysis

The global In-Vitro Colorectal Cancer Screening Tests market was worth USD 0.50 billion in the year 2012 and is expected to reach approximately USD 0.85 billion by 2022, while registering itself at a compound annual growth rate (CAGR) of 5.39% during the forecast period. Developing rates of rectal and colon cancer and the advent of novel screening tests utilizing genetic testing are the key elements that are anticipated to drive the in-vitro colorectal cancer screening tests market over the conjecture time frame. The advent of government controls went for compulsory use of cancer screening tests, increasing requirement for novel minimally invasive tests which screen for colorectal cancer utilizing genetic and DNA biomarkers and the expanding commonness of colorectal disease are foreseen to fuel the development of the market for in-vitro colorectal cancer screening tests. Comprehensively, colorectal cancer (CRC) is the third most common type of cancer. CRC represents right around a tenth of all disease occurrences around the world. This rate has just been expanding in the course of the most recent few years. Moreover, the advent of novel colorectal tests which utilize biomarkers, for example, tumor M2-PK marker or which screen for colorectal disease utilizing methylated genes for screening will witness a development in market demand all through the gauge time frame. The essential factor in charge of this switch in pattern can be ascribed to by the expanded precision of screening which these more up to date genetic tests bring to the table.



Product Outlook and Trend Analysis

The worldwide in-vitro colorectal cancer screening tests market was observed to be ruled by fecal mysterious blood tests attributable to their higher utilization rates and simple relevance to extensive gatherings of the populace on the double for cancer screening. The biggest share of the market for in-vitro colorectal screening tests was observed to be possessed Immuno-FOB ELISA and Immuno-FOB agglutination tests in 2014. Nonetheless, the development and investigation of more up to date more precise techniques for in-vitro colorectal cancer screening have prompted the advancement of biomarker and DNA screening tests. The most recent improvements in the screening tests are the methylated gene testing and transferrin assays. Amid the initial phases of cancer and before the genuine tumors spread over the human body, fixation examination of transferrin can give important data in the screening of precancerous lesions. Transferrin dipstick test has reflected precision reliable qualities with Immuno-FOB stool tests and attributable to their simpler appropriateness is anticipated to gain development all through the figure time frame. Likewise, testing for the existence of extreme gene methylation to decide the level of danger of development of colorectal cancer is additionally anticipated that would pick up share of the market in the upcoming years.

Regional Outlook and Trend Analysis

In 2014 the in-vitro colorectal cancer screening tests market was dominated by North America. Factors, for example, rising aged population, high rates of colorectal cancer has added to the district's market position. Nonetheless, Asia-Pacific is relied upon to witness generous development over the figure time frame attributable to the expanding commonness of cancer in this area. Cancer is a developing concern inferable from rising elderly populace base and changes in way of life in Asian nations. In-vitro colorectal cancer is the third most harmful issue in men and women. The death rates of colorectal cancer are on an ascent in this locale over the previous decade. National rules on colorectal cancer screening are nonexistent in most Asian nations aside from in Taiwan, Singapore, Japan, and Korea.

Competitive Insights

The in-vitro colorectal cancer screening tests market is extremely focused set apart by constant key partnerships, mergers, and acquisitions. Coordinated efforts are essentially utilized as a technique to upgrade item portfolio. The market is anticipated to move towards union throughout the following years. Research and development spending is relied upon to keep on growing, as most market players are associated with the improvement of CRC DNA and biomarker screening tests. Some of the major players in the market are R-Biopharm, Epigenomics AG, Sysmex Corporation, Quest Diagnostics, Merck Millipore, Kyowa Medex, Companion Dx, Abbott Molecular Inc, Immunostics Co, MODE Diagnostics Ltd, Siemens Healthineers and Randox Laboratories.

The In-Vitro Colorectal Cancer Screening Tests Market is segmented as follows-

By Product


Biomarker Tests


Transferrin Assays
Tumor M2-PK Stool Test


Fecal Occult Blood Tests

Lateral Flow Immuno-FOB Test
Guaiac FOB Stool Test
Immuno-FOB Agglutination Test
Immuno-FOB ELISA Test


CRC DNA Screening Tests

Panel DNA Tests
Methylated Gene Testing




By Region


North America



U.S
Canada
Mexico



Europe



Germany
France
UK
Italy
Spain
Rest of Europe



Asia-Pacific



Japan
China
Australia
India
South Korea
Rest of Asia Pacific



Rest of the World



Brazil
South Africa
Saudi Arabia
United Arab Emirates
Others


Some of the key questions answered by the report are:


What was the market size in 2012 and forecast from 2013 to 2022`
What will be the industry market growth from 2013 to 2022`
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast`
What are the major segments leading the market growth and why`
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition`

Table of Content

Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Rising Incidence of Rectal and Colon Cancer around the World
3.2.1.2. Enhanced Accuracy of Colorectal Cancer Screening Using Genetic Testing
3.2.1.3. Strong Product Pipeline
3.2.2. Restraints
3.2.2.1. Unfavorable Reimbursement Policies
3.2.2.2. Dearth of Skilled Professionals
3.2.3. Opportunities
3.2.3.1. Emerging Economies to Offer Lucrative Growth Opportunities
4. In-Vitro Colorectal Cancer Screening Tests Market, By Product
4.1. Introduction
4.2. In-Vitro Colorectal Cancer Screening Tests Market Assessment and Forecast, By Product, 2012-2022
4.3. Fecal Occult Blood Tests
4.3.1. Market Assessment and Forecast, By Type, 2012-2022 ($Million)
4.3.2. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.3.3. Guaiac FOB Stool Test
4.3.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.3.4. Lateral Flow Immuno-FOB Test
4.3.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.3.5. Immuno-FOB Agglutination Test
4.3.5.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.3.6. Immuno-FOB ELISA Test
4.3.6.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.4. Biomarker Tests
4.4.1. Market Assessment and Forecast, By Type, 2012-2022 ($Million)
4.4.2. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.4.3. Transferrin Assays
4.4.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.4.4. Tumor M2-PK Stool Test
4.4.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5. CRC DNA Screening Tests
4.5.1. Market Assessment and Forecast, By Type, 2012-2022 ($Million)
4.5.2. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5.3. Panel DNA Tests
4.5.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5.4. Methylated Gene Testing
4.5.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5. In-Vitro Colorectal Cancer Screening Tests Market, By Region
5.1. Introduction
5.2. In-Vitro Colorectal Cancer Screening Tests Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.3. North America
5.3.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
5.3.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.3.3. U.S.
5.3.3.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.3.4. Canada
5.3.4.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.3.5. Mexico
5.3.5.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.4. Europe
5.4.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
5.4.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.4.3. Germany
5.4.3.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.4.4. France
5.4.4.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.4.5. UK
5.4.5.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.4.6. Italy
5.4.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.4.7. Spain
5.4.7.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.4.8. Rest of Europe
5.4.8.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.5. Asia-Pacific
5.5.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
5.5.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.5.3. Japan
5.5.3.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.5.4. China
5.5.4.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.5.5. Australia
5.5.5.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.5.6. India
5.5.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.5.7. South Korea
5.5.7.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.5.8. Rest of Asia-Pacific
5.5.8.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.6. Rest of the World
5.6.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
5.6.2. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.6.3. Brazil
5.6.3.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.6.4. Turkey
5.6.4.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.6.5. Saudi Arabia
5.6.5.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.6.6. South Africa
5.6.6.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.6.7. United Arab Emirates
5.6.7.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
5.6.8. Others
5.6.8.1. Market Assessment and Forecast, By Product, 2012-2022 ($Million)
6. Company Profiles
6.1. Abbott Molecular Inc
6.1.1. Business Overview
6.1.2. Product Portfolio
6.1.3. Key Financials
6.1.4. Strategic Developments
6.2. Alere Inc.
6.2.1. Business Overview
6.2.2. Product Portfolio
6.2.3. Key Financials
6.2.4. Strategic Developments
6.3. Eiken Chemical
6.3.1. Business Overview
6.3.2. Product Portfolio
6.3.3. Strategic Developments
6.4. Beckman Coulter Inc
6.4.1. Business Overview
6.4.2. Product Portfolio
6.4.3. Key Financials
6.4.4. Strategic Developments
6.5. Epigenomics AG Corporation
6.5.1. Business Overview
6.5.2. Product Portfolio
6.5.3. Key Financials
6.5.4. Strategic Developments
6.6. Sysmex Corporation
6.6.1. Business Overview
6.6.2. Product Portfolio
6.6.3. Key Financials
6.6.4. Strategic Developments
6.7. Quest Diagnostics Incorporated
6.7.1. Business Overview
6.7.2. Product Portfolio
6.7.3. Key Financials
6.7.4. Strategic Developments
6.8. Siemens Healthcare Ltd.
6.8.1. Business Overview
6.8.2. Product Portfolio
6.8.3. Key Financials
6.8.4. Strategic Developments
6.9. OncoCyte Corporation-Biotime
6.9.1. Business Overview
6.9.2. Product Portfolio
6.9.3. Key Financials
6.9.4. Strategic Developments
6.10. CompanianDx
6.10.1. Business Overview
6.10.2. Product Portfolio
6.10.3. Key Financials
6.10.4. Strategic Developments
6.11. GeneNews Ltd.
6.11.1. Business Overview
6.11.2. Product Portfolio
6.11.3. Key Financials
6.11.4. Strategic Developments
6.12. R-Biopharm Incorporation
6.12.1. Business Overview
6.12.2. Product Portfolio
6.12.3. Key Financials

6.12.4. Strategic Developments


Table of Figures

Table 1.Global In-Vitro Colorectal Cancer Screening Tests Market, By Product ($Million), 2012-2022
Table 2.Fecal Occult Blood Tests Market, By Type ($Million), 2012-2022
Table 3.Fecal Occult Blood Tests Market, By Region ($Million), 2012-2022
Table 4.Guaiac FOB Stool Test Market, By Region ($Million), 2012-2022
Table 5.Lateral Flow Immuno-FOB Test Market, By Region ($Million), 2012-2022
Table 6.Immuno-FOB Agglutination Test Market, By Region ($Million), 2012-2022
Table 7.Immuno-FOB ELISA Test Market, By Region ($Million), 2012-2022
Table 8.Biomarker Tests Market, By Type ($Million), 2012-2022
Table 9.Biomarker Tests Market, By Region ($Million), 2012-2022
Table 10.Transferrin Assays Market, By Region ($Million), 2012-2022
Table 11.Tumor M2-PK Stool Test Market, By Region ($Million), 2012-2022
Table 12.CRC DNA Screening Tests Market, By Type ($Million), 2012-2022
Table 13.CRC DNA Screening Tests Market, By Region ($Million), 2012-2022
Table 14.Panel DNA Tests Market, By Region ($Million), 2012-2022
Table 15.Methylated Gene Testing Market, By Region ($Million), 2012-2022


Table 16.In-Vitro Colorectal Cancer Screening Tests Market, By Region ($Million), 2012-2022
Table 17.North America In-Vitro Colorectal Cancer Screening Tests Market, By Country, 2012-2022 ($Million)
Table 18.North America In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 19.U.S. In-Vitro Colorectal Cancer Screening Tests Market, by Product, 2012-2022 ($Million)
Table 20.Canada In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 21.Mexico In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 22.Europe In-Vitro Colorectal Cancer Screening Tests Market, By Country, 2012-2022 ($Million)
Table 23.Europe In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 24.Germany In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 25.France In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 26.UK In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 27.Italy In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 28.Spain In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 30.Rest of Europe In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 31.Asia-Pacific In-Vitro Colorectal Cancer Screening Tests Market, By Country, 2012-2022 ($Million)
Table 32.Asia-Pacific In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 33.Japan In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 34.China In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 35.Australia In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 36.India In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 37.South Korea In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 39.Rest of Asia-Pacific In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 40.Rest of the World In-Vitro Colorectal Cancer Screening Tests Market, By Country, 2012-2022 ($Million)
Table 41.Rest of the World In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 42.Brazil In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 43.Turkey In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 44.Saudi Arabia In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 45.South Africa In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 46.United Arab Emirates In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 47.Others In-Vitro Colorectal Cancer Screening Tests Market, By Product, 2012-2022 ($Million)
Table 48.Abbott Molecular Inc.: Key Strategic Developments, 2015-2017
Table 49.Alere Inc.: Key Strategic Developments, 2015-2017
Table 50 Eiken Chemical: Key Strategic Developments, 2015-2017
Table 51.Beckman Coulter Inc: Key Strategic Developments, 2015-2017
Table 52 .Epigenomics AG Corporation: Key Strategic Developments, 2015-2017
Table 53.Sysmex Corporation: Key Strategic Developments, 2015-2017
Table 54.Quest Diagnostics Incorporated: Key Strategic Developments, 2015-2017
Table 55.Siemens Healthcare Ltd.: Key Strategic Developments, 2015-2017
Table 56.OncoCyte Corporation-Biotime: Key Strategic Developments, 2015-2017
Table 57.CompanianDx: Key Strategic Developments, 2015-2017
Table 58.GeneNews Ltd.: Key Strategic Developments, 2015-2017
Table 59.R-Biopharm Incorporation: Key Strategic Developments, 2015-2017

Request Sample

* mark fields are compulsory